Novel Isoprenoyl Nanoassembled Prodrug for Paclitaxel Delivery

被引:43
作者
Mura, Simona [1 ,2 ]
Zouhiri, Fatima [1 ,2 ]
Lerondel, Stephanie [3 ]
Maksimenko, Andrei [1 ,2 ]
Mougin, Julie [1 ,2 ]
Gueutin, Claire [1 ,2 ]
Brambilla, Davide [1 ,2 ]
Caron, Joachim [1 ,2 ]
Sliwinski, Eric [1 ,2 ]
LePape, Alain [3 ,4 ]
Desmaele, Didier [1 ,2 ]
Couvreur, Patrick [1 ,2 ]
机构
[1] Univ Paris 11, Fac Pharm, F-92296 Chatenay Malabry, France
[2] CNRS, Inst Galien Paris Sud, UMR 8612, F-92296 Chatenay Malabry, France
[3] CNRS, CIPA, TAAM UPS44, F-45071 Orleans, France
[4] Univ Tours, INSERM, Res Ctr Resp Dis, U1100,EA 6305, F-37032 Tours, France
基金
欧洲研究理事会;
关键词
WATER-SOLUBLE PRODRUGS; ANTITUMOR-ACTIVITY; IN-VIVO; DRUG-DELIVERY; BREAST-CANCER; CREMOPHOR-EL; BIOLOGICAL-ACTIVITY; POLYMERIC MICELLES; FORMULATION VEHICLES; ACID-PACLITAXEL;
D O I
10.1021/bc400210x
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A new paclitaxel (Ptx) prodrug was designed by coupling a single terpene unit (MIP) to the hydroxyl group in position 2' of the drug molecule. Using a squalene derivative of polyethylene glycol (SQ-PEG) as surface active agent, the resulting bioconjugate (PtxMIP) self-assembled in water leading to the formation of stable nanoparticles (PtxMIP_SQ:PEG NPs) with an impressively high drug loading (82%). In vivo, the anticancer activity of this novel Ptx nanoassembled prodrug was compared to the conventional Cremophor-containing formulation (Taxol) on a murine model of breast cancer lung metastasis induced by intravenous injection of 4T1 tumor cells, genetically modified to stably express firefly luciferase. Cell growth was assessed noninvasively by bioluminescence imaging (BLI) which enabled monitoring tumor metastatic burden in the same animals. PtxMIP_SQ-PEG nanoparticles slowed metastatic spread and were better tolerated than the Cremophor-containing formulation (i.e., free drug), thus demonstrating the potential of terpene-based nanoassembled prodrugs in the improvement of the therapeutic index of Ptx in balb/c mice.
引用
收藏
页码:1840 / 1849
页数:10
相关论文
共 82 条
[1]   Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities [J].
Ali, S ;
Ahmad, I ;
Peters, A ;
Masters, G ;
Minchey, S ;
Janoff, A ;
Mayhew, E .
ANTI-CANCER DRUGS, 2001, 12 (02) :117-128
[2]   A MIXED MICELLAR FORMULATION SUITABLE FOR THE PARENTERAL ADMINISTRATION OF TAXOL [J].
ALKANONYUKSEL, H ;
RAMAKRISHNAN, S ;
CHAI, HB ;
PEZZUTO, JM .
PHARMACEUTICAL RESEARCH, 1994, 11 (02) :206-212
[3]  
Ansell S., 1996, U.S. Patent, Patent No. [5,534,499, 5534499]
[4]  
ASLAKSON CJ, 1992, CANCER RES, V52, P1399
[5]   Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma [J].
Bedikian, A. Y. ;
DeConti, R. C. ;
Conry, R. ;
Agarwala, S. ;
Papadopoulos, N. ;
Kim, K. B. ;
Ernstoff, M. .
ANNALS OF ONCOLOGY, 2011, 22 (04) :787-793
[6]   Novel PEGylated Nanoassemblies Made of Self-Assembled Squalenoyl Nucleoside Analogues [J].
Bekkara-Aounallah, Fawzia ;
Gref, Ruxandra ;
Othman, Mohammad ;
Reddy, L. Harivardhan ;
Pili, Barbara ;
Allain, Vanessa ;
Bourgaux, Claudie ;
Hillaireau, Herve ;
Lepetre-Mouelhi, Sinda ;
Desmaele, Didier ;
Nicolas, Julien ;
Chafi, Noja ;
Couvreur, Patrick .
ADVANCED FUNCTIONAL MATERIALS, 2008, 18 (22) :3715-3725
[7]   PLGA Nanoparticles Stabilized with Cationic Surfactant: Safety Studies and Application in Oral Delivery of Paclitaxel to Treat Chemical-Induced Breast Cancer in Rat [J].
Bhardwaj, V. ;
Ankola, D. D. ;
Gupta, S. C. ;
Schneider, M. ;
Lehr, C. -M. ;
Kumar, M. N. V. Ravi .
PHARMACEUTICAL RESEARCH, 2009, 26 (11) :2495-2503
[8]  
Bradley MO, 2001, CLIN CANCER RES, V7, P3229
[9]   Improving the Antitumor Activity of Squalenoyl-Paclitaxel Conjugate Nanoassemblies by Manipulating the Linker between Paclitaxel and Squalene [J].
Caron, Joachim ;
Maksimenko, Andrei ;
Wack, Severine ;
Lepeltier, Elise ;
Bourgaux, Claudie ;
Morvan, Estelle ;
Leblanc, Karine ;
Couvreur, Patrick ;
Desmaele, Didier .
ADVANCED HEALTHCARE MATERIALS, 2013, 2 (01) :172-185
[10]   Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery [J].
Chen, XY ;
Plasencia, C ;
Hou, YP ;
Neamati, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :1098-1106